---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Heterogeneity of treatment effect"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Heterogeneity of treatment effect. Topics: Ersodetug: tumor types enrolled and participants not yet responding in upLIFT, preliminary; Ersodetug: non-responder with advanced cancer and poor performance status, upLIFT interim; Ersodetug: dose escalation and partial response in the expanded access series; Comparator therapies: effectiveness differs between insulin-mediated and IGF-2-mediated hypoglycemia; 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Ersodetug: tumor types enrolled and participants not yet responding in upLIFT, preliminary

> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”
> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.3-2"></a>

### Ersodetug: response by tumor type (insulinoma or NICTH) in upLIFT

No evidence found.

<a id="topic-2.2.2.3-3"></a>

### Ersodetug: non-responder with advanced cancer and poor performance status, upLIFT interim

> “This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4).”
> “The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.3-4"></a>

### Ersodetug: dose escalation and partial response in the expanded access series

> “One participant required escalation from 9 to 12 mg/kg every other week.”
> “One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.3-5"></a>

### Comparator therapies: effectiveness differs between insulin-mediated and IGF-2-mediated hypoglycemia

> “DZ and SSAs do not work in NICTs because HI is not mediated by insulin”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Diazoxide and octreotide have no role in NICTH.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.3-6"></a>

### Comparator therapies: somatostatin receptor expression in indolent and aggressive insulinoma

> “Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas”
> “This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.3-7"></a>

### PRRT: tumor grade and recurrence of hypoglycemia

> “Patients with recurrent hypoglycaemia had a longer time to hypoglycaemia resolution (median 3.0 vs 0.5 months), were more likely G3 (57 vs 0%) and experienced higher mortality (86 vs 29%).”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

> “The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3”

Source: [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/)

<a id="topic-2.2.2.3-8"></a>

### Hepatic artery embolization: timing of hypoglycemia recurrence and survival

> “Recurrence of hypoglycemia within 6 weeks of the first HAE was associated with a median OS of 8.5 months, and recurrence greater than 6 weeks post-HAE was associated with a median OS of 32.6 months (P = .03)”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.2.3-9"></a>

### NICTH: tumor origin and chronic liver disease as outcome modifiers

> “Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).”
> “Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
